High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. - Wikidata - awgldk - TriplyDB

High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.

High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.

http://www.wikidata.org/entity/Q36545353

about

Checkpoint Inhibitors and Their Application in Breast Cancer Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma.Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma.Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients.Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.Basis for molecular diagnostics and immunotherapy for esophageal cancer.PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.PD-L1 and intratumoral immune response in breast cancer.Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.Type Iγ phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-κB.Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.CD4+T cell specific B7-H1 selectively inhibits proliferation of naïve T cells and Th17 differentiation in experimental autoimmune encephalomyelitis.PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.In-vitro effect of pembrolizumab on different T regulatory cell subsets.Improvement of cytotoxicity of autologous CIKs from patients with breast cancer to MCF-7 cells by suppressed PD-1 expression.Prognostic value of PD -L1 expression in patients with primary solid tumors.The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma.Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.PD-L1 Expression and CD8+ T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer.

P2860

Q26745442-94E6AA06-AD3D-4CCE-A29E-DEA940A40468 Q33644049-176C48D2-1ABB-49F5-88A7-60F1057442B4 Q33709601-F2B9005D-6A12-4283-835E-C5D198B4BACC Q33736377-234180E8-2D4A-4572-972A-0F6DB794D933 Q36030084-37EA69EC-836C-45F8-B99A-F5C7C5249DC6 Q36353438-4E6ED3C4-684D-4556-9EC6-91467B725045 Q37026725-D6A671DD-B221-4B15-9C7A-7D0FE16FCCBC Q37362830-D97D0544-870F-4357-93FD-8A248015CE9B Q37362929-CB620C65-7D03-49C2-94AA-F769BDF49449 Q37564425-E2440699-FD99-41CD-8638-F3EC061FA872 Q37644975-69E6FCEB-A6CE-4605-B207-1FDDE440BB62 Q37716582-F5CCBF6E-878F-4F73-9FF7-3288034C82A0 Q38629357-3B52D6E6-6918-4FB9-97DE-68B0CDD0BA4A Q39006844-C85E53AC-1F4D-432F-88A2-255C310DB988 Q39036924-09DEC5A6-175B-46D5-978A-D3748E34C734 Q41579669-16CD82C5-FB46-46B9-8E59-B7B135A1384A Q41612935-2C84071D-FAF1-4F6B-98BB-2F318D5D45D5 Q41718196-22E62A41-CCC8-4082-8348-97AE9F6E97DA Q41964740-5751D1D4-3800-4707-85B9-0130CBEBCBCA Q42682646-9A9B029F-6896-4CC4-8F63-9110A89D5E36 Q47093886-6936D45A-70C0-4A4E-B75B-146853784D7C Q47109363-8B2420B0-C165-4CFF-A192-E5AD10DE739D Q47113036-A9B44C2E-F7CC-4A1D-97F8-264FEC732BD4 Q47134535-C757899B-DCFA-4FB0-BF8F-92016CF4D3C2 Q47139579-6428C05C-3F14-4239-85A4-534252ED9E33 Q47289144-014FA525-080B-4867-A44C-A2AEC882CDD7 Q47291286-DE9FE5C0-6FE8-4ABA-B5E2-AA3E1F240E8C Q47616276-0B80FDE8-9BEB-4897-928A-EC169E00F6F2 Q47860781-02951938-C48B-4766-8BAF-27B4802227C9 Q49732572-789EAF19-37D2-46C7-850C-18745A18F9F9 Q50070938-7F285904-AA0B-4C26-9A8F-96C5FD74E3B4 Q55138887-FFD91E44-44DD-4446-9787-A73D4175E9AC Q55278765-9ECDD7B8-2D68-4AE3-9B22-92D0351C9A97 Q55554951-C4F1E7D3-1443-44F5-AFFD-5CFABE073542

P2860

High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.

http://www.wikidata.org/entity/Q36545353

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

High PD-L1 expression was asso ...... e patients with breast cancer.

@ast

High PD-L1 expression was asso ...... e patients with breast cancer.

@en

type

label

High PD-L1 expression was asso ...... e patients with breast cancer.

@ast

High PD-L1 expression was asso ...... e patients with breast cancer.

@en

prefLabel

High PD-L1 expression was asso ...... e patients with breast cancer.

@ast

High PD-L1 expression was asso ...... e patients with breast cancer.

@en

P1433

Q36545353-DC55DB62-F9C2-44AE-9E29-3C81C73F415C

P1476

Q36545353-1D6BE48D-6081-4492-9F3C-1BB1F9D41BC5

P2093

Q36545353-032A2FB3-8971-4A41-A68C-AE737EEF7D04

Q36545353-06766ACD-9E8E-425A-9C14-BEFF2C67851B

Q36545353-23D5F5E3-ADE8-4AC5-8D6F-16D9BC3004D8

Q36545353-245FAD5D-6465-4C84-B988-6A47E7105ED0

Q36545353-50DF07B5-9BD5-43DB-BC6B-699B26605E74

Q36545353-63C52281-446F-42F3-AAF2-219B93A4B5C7

Q36545353-8141ED77-F225-496C-94F9-CDCF0DECB091

Q36545353-9717DA3A-2105-4F0C-82D3-2A9C1722A676

Q36545353-A037C504-159E-43CC-98B4-845082E8E9AF

Q36545353-C4D247DE-AEAB-4B84-9B30-EA6892A8EE92

P2860

Q36545353-02CF0080-F82B-448F-B900-254379471D2B

Q36545353-0798CA58-C20B-4A2F-85E7-D744E3E3A9D6

Q36545353-0E2F03B6-0DF5-45B6-966C-0EFB7C43E09D

Q36545353-192E8C3F-5534-48C3-995A-10831B681C5E

Q36545353-1EF1695B-4A40-403D-A1FE-A62E1BA3CC62

Q36545353-22903AEE-1102-4813-9870-6F36EF10B311

Q36545353-3469D8AD-40DA-467C-BED5-DEE3F7B37A69

Q36545353-3B4145F3-6486-4AC0-B6E1-4CBADD1845DF

Q36545353-3E8E62DD-9A71-4D44-BEBE-59D2E627E35B

Q36545353-5054F6B0-8C39-45B6-8773-E70BB2601878

P304

Q36545353-409B3F43-A0D4-401C-8CBD-FEE43915CB7E

P31

Q36545353-97E0B599-2442-47F2-8FFE-0563E56C36A9

P356

Q36545353-7AEA84E6-C9F5-41E5-83E3-9431A2C703F5

P407

Q36545353-39128CF1-7011-4FEF-AF66-C9ED14628B03

P433

Q36545353-BC54CFD9-91D3-4B7D-A1C8-E0CC58B13FF7

P478

Q36545353-7EA19C1B-F2F5-4CFD-93EA-272DDE86E859

P577

Q36545353-30DA68A2-3EF7-4E98-BF81-E4C371DE4CD1

P5875

Q36545353-01A7CAA5-6B6A-425D-8536-5AFC7DB4CC67

P698

Q36545353-4E3FBB4D-6870-4214-87B4-8253A2E509B9

P932

Q36545353-38720D88-8050-45C6-8C5F-E5F6770DC83F

P356

ONCOTARGET.5583

P1433

P1476

High PD-L1 expression was asso ...... e patients with breast cancer.

@en

P2093

Cong Xue

http://www.w3.org/2001/XMLSchema#string

Fei Xu

http://www.w3.org/2001/XMLSchema#string

Ge Qin

http://www.w3.org/2001/XMLSchema#string

Jia-bin Lu

http://www.w3.org/2001/XMLSchema#string

Jian-hua Zhan

http://www.w3.org/2001/XMLSchema#string

Li Zhang

http://www.w3.org/2001/XMLSchema#string

Qiu-fan Zheng

http://www.w3.org/2001/XMLSchema#string

Rou-jun Peng

http://www.w3.org/2001/XMLSchema#string

Shu-sen Wang

http://www.w3.org/2001/XMLSchema#string

Tao Qin

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2012

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Breast cancer metastasis: markers and models

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

PD-L1 expression is increased in a subset of basal type breast cancer cells.

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

Prognostic and predictive value of PDL1 expression in breast cancer.

PD-1/PD-L1 inhibitors.

P304

33972-33981

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.5583

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

282042453

http://www.w3.org/2001/XMLSchema#string

P698

26378017

http://www.w3.org/2001/XMLSchema#string

P932

4741818

http://www.w3.org/2001/XMLSchema#string